TScan Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
TScan Therapeutics Stock-Based Compensation Growth & History (TCRX)
TScan Therapeutics's stock-based compensation was $11.7M for fiscal 2025.
View full TScan Therapeutics company overviewTScan Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.7M | $2.2M | +22.59% |
| 2024 | 2024-12-31 | $9.5M | $4.3M | +83.35% |
| 2023 | 2023-12-31 | $5.2M | $657,000 | +14.44% |
| 2022 | 2022-12-31 | $4.6M | $2.0M | +80.88% |
| 2021 | 2021-12-31 | $2.5M | $2.0M | +388.54% |
| 2020 | 2020-12-31 | $515,000 | — | — |
TScan Therapeutics quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.4M | −$916,000 | −27.99% |
| Q1 2026 | 2026-03-31 | $2.5M | −$949,000 | −27.80% |
| Q4 2025 | 2025-12-31 | $2.0M | −$706,000 | −26.01% |
| Q3 2025 | 2025-09-30 | $3.0M | $488,000 | +19.34% |
| Q2 2025 | 2025-06-30 | $3.3M | $945,000 | +40.59% |
| Q1 2025 | 2025-03-31 | $3.4M | $1.4M | +72.08% |
| Q4 2024 | 2024-12-31 | $2.7M | $1.2M | +80.93% |
| Q3 2024 | 2024-09-30 | $2.5M | $1.2M | +88.14% |
| Q2 2024 | 2024-06-30 | $2.3M | $1.1M | +90.82% |
| Q1 2024 | 2024-03-31 | $2.0M | $837,000 | +72.97% |
| Q4 2023 | 2023-12-31 | $1.5M | $203,000 | +15.65% |
| Q3 2023 | 2023-09-30 | $1.3M | $95,000 | +7.62% |
| Q2 2023 | 2023-06-30 | $1.2M | $196,000 | +19.14% |
| Q1 2023 | 2023-03-31 | $1.1M | $163,000 | +16.57% |
| Q4 2022 | 2022-12-31 | $1.3M | $513,000 | +65.43% |
| Q3 2022 | 2022-09-30 | $1.2M | $361,000 | +40.79% |
| Q2 2022 | 2022-06-30 | $1.0M | $521,000 | +103.58% |
| Q1 2022 | 2022-03-31 | $984,000 | $640,000 | +186.05% |
| Q4 2021 | 2021-12-31 | $784,000 | — | — |
| Q3 2021 | 2021-09-30 | $885,000 | $756,000 | +586.05% |
| Q2 2021 | 2021-06-30 | $503,000 | $377,000 | +299.21% |
| Q1 2021 | 2021-03-31 | $344,000 | — | — |
| Q3 2020 | 2020-09-30 | $129,000 | — | — |
| Q2 2020 | 2020-06-30 | $126,000 | — | — |
TScan Therapeutics stock-based compensation trends
Over the last five fiscal years, TScan Therapeutics's stock-based compensation increased from $515,000 to $11.7M, a change of $11.2M. The latest reported quarter, Q2 2026, shows $2.4M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TScan Therapeutics source filings ↗